The global antibiotics market size is likely to project a CAGR of 5.14% during the forecast years 2021-2028. A significant factor driving the global antibiotics market is the rising prevalence of infectious illnesses throughout the world. Antibiotics have been a crucial tool in treating the huge burden of infectious illnesses globally since their discovery in the early twentieth century. Popular antibiotic compounds such as fluoroquinolone, broad spectrum penicillins and cephalosporin have constantly gained maximum adoption over the years, thus contributing massively towards stable growth in global antibiotics market. However, antimicrobial resistance (AMR) is a growing danger to antibiotic efficacy, which may limit their usage.
Adroit Market Research report on global antibiotics market gives a holistic view of the market, which includes factors such as market drivers, restraints, opportunities and challenges. The market has been studied for the period 2019 to 2028, with the base year of estimation as 2020 and forecast from 2021 to 2028. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the market based on Porter's five forces analysis and positions the key players based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global antibiotics market have been studied in detail.
Based on drug class, the global antibiotics market has been segmented into broad spectrum penicillins, cephalosporins, macrolides, quinolones, tetracyclines, narrow spectrum penicillins, trimethoprim & combinations, and others. The broad spectrum penicillins segment accounted for more than 36% of the total antibiotics market in 2020 and it is likely to maintain its place throughout the forecast years.
On the basis of route of administration, the global antibiotics market is categorized into oral and parenteral route. Oral route accumulated the largest market share in 2020, contributing to USD 31.25 billion. Increasing preference for the safe, less expensive and convenient intake of medicine by the patients along with the increasing number of product approvals for branded and generic oral antibiotics are factors expected to support the growth of this segment over the forecast period. Moreover, manufacturers are focusing on developing and commercializing oral antibiotics with time release formulations, as it offers added advantages of the convenience of dosing, improves compliance and results in less fluctuation in blood levels across the course of the day.
North America is anticipated to hold majority market share in the global antibiotics market by 2028. The United States is expected to have the largest share of the antibiotics market in North America. Increasing prevalence of infectious diseases along with the focus on the development of effective medicines on cholera, tuberculosis, typhoid, etc. are primary factors propelling demand for antibiotics in the region. Moreover, presence of prominent players such as Merck & Co., Inc., Abbott Laboratories, Pfizer Inc., and increasing investments for developing strong product pipelines targeting multi resistance drugs are other factors expected to propel the demand for antibiotics in North America.
The major players of the global antibiotics market are Abbott Laboratories, Merck & Co. Inc., GlaxoSmithKline Plc, F.Hoffmann-La Roche Ltd., Mylan N.V., Sanofi, Pfizer Inc., Novartis International AG, and Cipla Ltd. among others.
Key Segments of the Global Antibiotics Market
Drug Class Overview, 2019-2028 (USD Billion)
- Broad Spectrum Penicillins
- Narrow Spectrum Penicillins
- Trimethoprim & Combinations
Route of Administration Overview, 2019-2028 (USD Billion)
Regional Overview, 2019-2028 (USD Billion)
- Rest of Europe
- Rest of Asia Pacific
- Rest of South America
Middle East and Africa
- South Africa
- Rest of Middle East and Africa